Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of afuresertib alone and with bortezomib + dexamethasone in Japanese patients with relapsed multiple myeloma
jRCT2080222524Phase 1Completed
- Sponsor
- Novartis
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of afuresertib in multiple myeloma (MM) (2 arms), sponsored by Novartis. Primary endpoints: Tolerability and safety of afuresertib (monotherapy and in combination) and Pharmacokinetics of afuresertib. Started Jun 2014; status: completed.
02
Drugs
afuresertib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080222524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222524.